InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: jessellivermore post# 279727

Friday, 06/12/2020 1:33:42 PM

Friday, June 12, 2020 1:33:42 PM

Post# of 426172
JL-

Actually the rule in most cases is the cheapest alternative is awarded the Tier one and in most cases that is the generic..

Do you consider that a lot of plan tiering as:
1: preferred generics
2: non-preferred generics
3: preferred brand
2: non-preferred brand

Its just it will not be Amarin vs Lovaza it will be Teva {if they make gen Lovaza} against Reddi and Hikma..

a.) several companies produce gen Lovaza ... inc. TEVA
(b) TEVA will produce gen Vascepa also ... it will be Teva against Reddi and Hikma and TEVA ...

The same thing will happen to the generics unless they can sell gen Vascepa cheaper than gen Lovaza..(not likely)

How about the pricing of gen Lovaza by TEVA against gen Vascepa by TEVA ... ?

Best,
G

Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News